| Prev Close | 243.03 |
| Day Low/High | 231.74 / 247.95 |
| 52 Wk Low/High | 49.03 / 243.97 |
Medifast, Inc. (MED)
240.49
NYSE
| Exchange | NYSE |
| Shares Outstanding | 11.77B |
| Market Cap | 2.86B |
| P/E Ratio | 27.68 |
| Div & Yield | N.A. (N.A) |
Latest News
This Dividend Stock Is Tipping the Scales for Investors
As more Americans struggle with obesity, Medifast sees strength in weight-loss offerings.
5 Holiday Stock Ideas for Investors: Cook, Exercise and Sleep
Celebrate Thanksgiving with these specially selected picks for your portfolio.
The Week Ahead: Earnings Season Is Far From Over
Disney, Qualcomm and Square are among 75 key reports we are watching.
Post Holdings Plans to Shake Up the Market With a Spinoff
Post's IPO of its star Active Nutrition segment is expected to take place in the December quarter.
Beach Season Spurring Sales Says Medifast CEO
Shares of Medifast are in robust shape, up nine percent so far this year, heading into the weight loss provider's second busiest season of the year.
Oprah Adding Heft to Resolution Season Says Medifast CEO
New Year’s resolution season is the busiest time of the year in the weight loss industry.
4 Stocks That Are Fit for Fitness
These companies should feast as more obese Americans turn to exercise and healthy foods.
Second Half Looks Strong Despite Higher Ad Spending Says Medifast CEO
Medifast finished the first quarter ahead of where it wanted to be and the weight loss company is now gearing up for a strong second half, says CEO Michael MacDonald.
The Trend Is Still Healthy
Especially true after the weakness in overseas markets.
The Week Ahead: Some Welcome Surprises
Economic data seem to be shifting for the better.
Medifast Off to Fast Start Despite Nu Skin, Herbalife Hoopla
The start of diet season - January through April - looks bright for Medifast so far, says the company's CEO Michael MacDonald, as does Medifast's expansion plans into Canada.
Medifast Weighs In on Weight Loss War
Weight loss stocks have seen turmoil this summer, but Medifast CEO Michael MacDonald says his company will overcome the problems plaguing Herbalife and Weight Watchers.
Medifast CEO: Meal Replacement = Big Growth
Medifast CEO Mike MacDonald expects 19% growth in the meal replacement business.
Not Sold on the Uptrend
After last Friday's follow-through, the action has been unconvincing.
The Week Ahead: Earnings Schmearnings
While these reports should offer clarity, the election will clear a much bigger overhang on the market.
Weight Loss Pills Not a Threat, Says Medifast CEO
Mike MacDonald, CEO of Medifast, says the company's new franchise strategy is propelling its stock and recently approved weight loss pills are not a threat.
A Supplemental Strategy
Plenty of activity in the nutritional-supplements industry today.
A Stirring Performance From These Small-Caps
These under-the-radar stocks have done very well of late, and they have the fundamentals to back it up.
